(Q33416524)

26 July 2017

title

Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia (English)

1 reference

chronic lymphocytic leukemia

26 July 2017

0 references

1 reference

1 reference

1 reference

Arpita Shah

1

1 reference

26 July 2017

language of work or name

English

0 references

publication date

18 July 2014

1 reference

Annals of Pharmacotherapy

26 July 2017

published in

1 reference

26 July 2017

volume

48

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

1356-1361

1 reference

26 July 2017

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

A mechanism-driven treatment for chronic lymphocytic leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Monoclonal antibody therapy of chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Rituximab in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Drug monographs: afatinib and obinutuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Obinutuzumab: first global approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

How will B-cell-receptor-targeted therapies change future CLL therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028014543271

21 January 2018

Identifiers

DOI

10.1177/1060028014543271

1 reference

26 July 2017

1 reference